SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : NPSP NPS Pharmaceutical
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Miljenko Zuanic who wrote (182)11/20/2003 2:35:15 AM
From: Icebrg  Read Replies (2) of 363
 
No, not necessarily. The results are very eagerly awaited, so a CC is not out of place. But results may well be negative and in line with results seen with Evista. Evista was approved despite the negative results from their preclinical cancer study.

I held some shares for a brief period but sold because of the extraordinary number of form 4s issued. It seems as if everyone in management and the BoD sold shares at least once during the autumn.

If the cancer study against expectations should turn out positive it would be a huge advantage for NPSP as Preos would get a very strong selling point against Evista.

Erik
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News